Health Canada
Symbol of the Government of Canada
Drugs and Health Products

Monograph: Coenzyme Q10

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.



Date: 2007-11-22

NHPID Name

Coenzyme Q10 (Natural Standard 2009)

Proper Name(s)

2,5-Cyclohexadiene-1,4-dione, 2-[(2E ,6E ,10E ,14E ,18E ,22E ,26E , 30E ,34E )-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl ( USP 2008 )

Common Name(s)

Source Material


Route Of Administration

Oral

Dosage Form(s)

  • The acceptable pharmaceutical dosage forms include, but are not limited to capsules, chewables (e.g. gummies, tablets), liquids, powders, strips or tablets.
  • This monograph is not intended to include foods or food-like dosage forms such as bars, chewing gums or beverages.

Use(s) or Purpose(s)

Statement(s) to the effect of:

Dose(s)

Adults:

Cardiovascular health; Antioxidant
Dose(s): 30 - 100 Milligrams 1-3 times per day
Migraine prophylaxis
Dose(s): 75 - 100 Milligrams 2-3 times per day

Duration of use

Migraine prophylaxis: Use for a minimum of 3 months to see beneficial effects  (Hershey et al. 2007, Sandor et al. 2005, Rozen et al. 2002)

Risk Information

Statement(s) to the effect of:

Caution(s) and Warning(s):
  • Consult a health care practitioner prior to use if you are pregnant or breastfeeding
  • Consult a health care practitioner prior to use if you are taking blood pressure medication  (Rosenfeldt et al. 2007, Singh et al. 1999)
  • Doses greater than or equal to 100 Milligrams per day:
    Consult a health care practitioner prior to use if you are taking blood thinners  (Engelsen et al. 2003, Landbo and Almdal 1998, Spigset 1994)
  • Migraine prophylaxis:
    Consult a health care practitioner if migraine frequency increases, and associated nausea and vomiting persist or worsen

Contraindication(s):
No statement is required

Known Adverse Reaction(s):
No statement is required

Non-medicinal ingredients

Must be chosen from the current Natural Health Products Ingredients Database and must meet the limitations outlined in the database.

Specifications

  • The finished product specifications must be established in accordance with the requirements described in the NHPD Quality of Natural Health Products Guide.
  • The medicinal ingredient must comply with the requirements outlined in the Natural Health Products Ingredient Database (NHPID).

References cited

  • Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Molecular Aspects of Medicine 1994;15(Supplement 1):S287-S294.
  • Bonakdar RA, Guarneri E. Coenzyme Q10. American Family Physician 2005;72(6):1065-1070.
  • Chello M, Mastroroberto P, Romano R, Bevacqua E, Pantaleo D, Ascione R, Marchese AR, Spampinato N. Protection by Coenzyme Q10 from myocardial reperfusion injury during coronary artery bypass grafting. Annals of Thoracic Surgery 1994;58(5):1427-1432.
  • Crane FL. Biochemical functions of coenzyme Q10. Journal of the American College of Nutrition 2001;20(6):591-598.
  • Engelsen J, Nielsen JD, Hansen KF. [Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial]. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish).
  • EP 2005: European Pharmacopoeia. Strasbourg Cedex (France): Directorate for the Quality of Medicines of the Council of Europe (EDQM); 2005.
  • Hershey AD, Powers SW, Vockell AL, Lecates SL, Ellinor PL, Segers A, Burdine D, Manning P, Kabbouche MA. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47(1):73-80.
  • Kalpravidh RW, Wichit A, Siritanaratkul N, Fucharoen S. Effect of coenzyme Q10 as an antioxidant in beta-thalassemia/Hb E patients. BioFactors 2005;25(1-4):225-234.
  • Kawamukai M. Biosynthesis, bioproduction and novel roles of ubiquinone. Journal of Bioscience and Bioengineering 2002;94(6):511-517.
  • Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish).
  • Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Langsjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klinische Wochenschrift 1988;66(13):583-590.
  • Langsjoen PH. Introduction to coenzyme Q10. Online in: A Physician's Update on Coenzyme Q10 in U.S. Medicine. University of Washington faculty webpage of John T.A. Ely, Ph.D. Tyler (TX); 1994. [Accessed 2007-10-23]. Available from: http://faculty.washington.edu/ely/coenzq10.html.
  • Lipshutz BH, Lower A, Berl V, Schein K, Wetterich F. An improved synthesis of the "miracle nutrient" coenzyme Q10. Organic Letters 2005;7(19):4095-4097.
  • Lipshutz BH, Mollard P, Pfeiffer SS, Chrisman W. A short, highly efficient synthesis of coenzyme Q10. Journal of the American Chemical Society 2002;124(48):14282-14283.
  • O'Neil MJ, Smith A, Heckelman PE, Budavari S, editors. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th edition. Whitehouse Station (NJ): Merck & Co., Inc.; 2001.
  • Park YC, Kim SJ, Choi JH, Lee WH, Park KM, Kawamukai M, Ryu YW, Seo JH. Batch and fed-batch production of coenzyme Q10 in recombinant Escherichia coli containing the decaprenyl diphosphate synthase gene from Gluconobacter suboxydans. Applied Microbiology and Biotechnology 2005;67(2):192-196.
  • Rosenfeldt F, Marasco S, Lyon W, Wowk M, Sheeran F, Bailey M, Esmore D, Davis B, Pick A, Rabinov M, Smith J, Nagley P, Pepe S. Coenzyme Q10 therapy before cardiac surgery improves mitochondrial function and in vitro contractility of myocardial tissue. Journal of Thoracic Cardiovascular Surgery 2005;129(1):25-32.
  • Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306.
  • Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, Shechter AL, Silberstein SD. Open label trial of coenzyme Q10 as a migraine preventative. Cephalgia 2002;22(2):137-141.
  • Sandor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D, Seidel L, Agosti RM, Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005;64(4):713-715.
  • Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208.
  • Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373.
  • Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q10 Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Archives of Neurology 2007;64(7):938-944.
  • Sweetman SC , editor. Martindale: The Complete Drug Reference, 35th edition. London (UK): Pharmaceutical Press; 2007.
  • Szkopinska A. Review: Ubiquinone. Biosynthesis of quinone ring and its isoprenoid side chain. Intracellular localization. Acta Biochimica Polonica 2000;47(2):469-480.
  • Tanaka J, Tominaga R, Yoshitoshi M, Matsui K, Komori M, Sese A, Yasui H, Tokunaga K. Coenzyme Q10: the prophylactic effect on low cardiac output following cardiac valve replacement. Annals of of Thoracic Surgery 1982;33(2):145-151.
  • The United States Pharmacopeia and the National Formulary (USP 31/NF 26). 2008. Rockville (MD): United States Pharmacopeial Convention, Inc.
  • USP 30: United States Pharmacopeia and the National Formulary (USP 30 - NF 25). Rockville (MD): United States Pharmacopeial Convention, Inc.; 2007.
  • Yoshida H, Kotani Y, Ochiai K, Araki K. Production of ubiquinone-10 using bacteria. Journal of General and Applied Microbiology 1998;44(1):19-26.
  • Zhao J, Wang C, Sun X. [Determination of solanesol in the extracts of tobacco leaves by high performance liquid chromatography (HPLC)]. Chinese Journal of Chromatography 1997;15(6):544-545 (in Chinese).

References reviewed

  • Actis-Goretta L, Carrasquedo F, Fraga CG. The regular supplementation with an antioxidant mixture decreases oxidative stress in healthy humans. Gender effect. Clinica Chimica Acta 2004;349(1-2):97-103.
  • Aejmelaeus R, Metsa-Ketela T, Laippala P, Solakivi T, Alho H. Ubiquinol-10 and total peroxyl radical trapping capacity of LDL lipoproteins during aging: the effects of Q-10 supplementation. Molecular Aspects of Medicine 1997;18(Supplement 1):S113-S120.
  • Badmaev V, Majeed M, Prakash L. Piperine derived from black pepper increases plasma levels of coenzyme Q10 following oral supplementation. Journal of Nutritional Biochemistry 2000;11(2):109-113.
  • Barbiroli B, Frassineti C, Martinelli P, Iotti S, Lodi R, Cortelli P, Montagna P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology 1997;43(5):741-749.
  • Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di Giulio R, Battino M. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Internal Journal of Clinical Laboratory Research 1994;24(3):171-176.
  • Baumann L. How to prevent photoaging? The Journal of Investigative Dermatology 2005;125(4):xii-xiii.
  • Beal MF, Matthews RT. Coenzyme Q10 in the central nervous system and its potential usefulness in the treatment of neurodegenerative diseases. Molecular Aspects of Medicine 1997;18(Supplement 1):S169-S179.
  • Belardinelli R, Mucaj A, Lacalaprice F, Solenghi M, Principi F, Tiano L, Littarru GP. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. BioFactors 2005;25(1-4):137-145.
  • Bonetti A, Solito F, Carmosino G, Bargossi AM, Fiorella PL. Effect of ubidecarenone oral treatment on aerobic power in middle-aged trained subjects. Journal of Sports Medicine and Physical Fitness 2000;40(1):51-57
  • Boon H, Jurgens T. Drug interactions with natural health products: a discussion paper. In "Perspectives on Natural Health Products - A Collection of Executive Summaries from Stakeholder Consultation Reports, 2001-2002. Quality and Safety". Ottawa (ON): Natural Health Products Directorate, Health Canada; 2001. [Accessed 2007-10-23]. Available from: http://www.hc-sc.gc.ca/dhp-mps/pubs/complement/hp-ps_perspectives/hp-ps_perspectives_2_e.html1.
  • Braun B, Clarkson PM, Freedson PS, Kohl RL. Effects of coenzyme Q10 supplementation on exercise performance, VO2max, and lipid peroxidation in trained cyclists. International Journal of Sport Nutrition 1991;1(4):353-365.
  • Bresolin N, Doriguzzi C, Ponzetto C, Angelini C, Moroni I, Castelli E, Cossutta E, Binda A, Gallanti A, Gabellini S. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. Journal of Neurological Sciences 1990;100(1-2):70-78.
  • Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Medical Journal 2001;94(11):1112-1117.
  • Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. American Journal of Cardiology 2007;99(10):1409-1412.
  • Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology 1997;37(4):212-218.
  • Choi JH, Ryu YW, Seo JH. Biotechnological production and applications of coenzyme Q10. Applied Microbiology and Biotechnology 2005;68(1):9-15.
  • Cohen BH, Gold DR. Mitochondrial cytopathy in adults: what we know so far. Cleveland Clinical Journal of Medicine 2001;68(7):625-642.
  • De Pinieux G, Chariot P, Ammi-Saïd M, Louarn F, Lejonc JL, Astier A, Jacotot B, Gherardi R. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. British Journal of Clinical Pharmacology 1996;42(3):333-337.
  • Di Giovanni S, Mirabella M, Spinazzola A, Crociani P, Silvestri G, Broccolini A, Tonali P, Di Mauro S, Servidei S. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001;57(3):515-518.
  • Digiesi V, Cantini F, Oradei A, Bisi G, Guarino GC, Brocchi A, Bellandi F, Mancini M, Littarru GP. Treatment of essential hypertension with coenzyme Q10. Molecular Aspects of Medicine 1994;15(Supplement 1):S257-S263.
  • Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thrombosis and Haemostasis 2002;87(6):1075-1076.
  • Eriksson JG, Forsen TJ, Mortensen SA, Rohde M. The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. BioFactors 1999;9(2-4):315-318.
  • Eshginia S, Gapparov MM. [The influence of phospholipids food and antioxidant at patients with hypertension]. Voprosy Pitaniia 2006;75(2):37-39 (in Russian).
  • Fang LC, Huang XF, Du ZH, Yuan J, Wei H, Cheng HH, Liu Y. [Isolation and identification of a photosynthetic bacteria producing coenzyme Q10]. Wei Sheng Wu Xue Bao 2005;45:772-775 (in Chinese).
  • Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005;65(11):1834-1836.
  • Folkers K, Simonsen R. Two successful double-blind trial with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta 1995;1271(1):281-286.
  • Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proceedings of the National Academy of Science 1985;82(13):4513-4516.
  • Gazdikova K, Gvozdjakova A, Kucharska J, Spustova V, Braunova Z, Dzurik R. [Effect of coenzyme Q10 in patients with kidney diseases]. Casopis Lekarska Ceskych 2001;140(10):307-310 (in Slovak).
  • Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, Greco AV, Littarru GP. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. Journal of Clinical Pharmacology 1993;33(3):226-229.
  • Giovannini L, Bertelli AA, Scalori V, Dell'Osso L, Alessandri MG, Mian M. Skin penetration of CoQ10 in the rat. International Journal of Tissue Reactions 1988;10(2):103-105.
  • Hanioka T, Tonaka M, Ojima M, Shizukuishi S, Folkers K. Effect of topical application of coenzyme Q10 on adult periodontitis. Molecular Aspects of Medicine 1994;15(Supplement 1):S241-S248.
  • Hathcock JN, Shao A. Risk assessment for coenzyme Q10 (ubiquinone). Regulatory Toxicology and Pharmacology 2006;45(3):282-288.
  • Health Canada. MedEffect Canada: Adverse Reaction Reporting. Ottawa (ON): Health Canada; 2007. [Accessed 2012-01-30]. Available from: http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index_e.html.
  • Hendler SS, Rorvik D, editors. PDR for Nutritional Supplements, 1st edition. Montvale (NJ): Thomson PDR; 2001.
  • Henriksen JE, Andersen CB, Hother-Nielsen O, Vaag A, Mortensen SA, Beck-Nielsen H. Impact of ubiquinone (coenzyme Q10) treatment on glycaemic control, insulin requirement and well-being in patients with Type 1 diabetes mellitus. Diabetic Medicine 1999;16(4):312-318.
  • Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. European Journal of Clinical Nutrition 2002;56(11):1137-1142.
  • Hoppe U, Bergemann J, Diembeck W, Ennen J, Gohla S, Harris I, Jacob J, Kielholz J, Mei W, Pollet D, Schachtschabel D, Sauermann G, Schreiner V, Stab F, Steckel F. Coenzyme Q10, acutaneous antioxidant and energizer. BioFactors 1999;9(2-4):371-378.
  • Huertas JR, Palomino N, Carrasco R, Quiles J, Ramirez-Tortosa MC, Ochoa J, Cassinello M, Battino M, Robles R, Mataix J. Lipid peroxidation and antioxidants in newborns. Molecular Aspects of Medicine 1997;18(Supplement 1):S229-S232.
  • Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M, Casale F, Indolfi P, Iacono A. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molecular Aspects of Medicine 1994;15(Supplement 1):S207-S212.
  • Isobe C, Murata T, Sato C, Terayama Y. Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. Journal of Clinical Neuroscience 2007;14(4):340-343.
  • Jellin JM. Natural Medicines Comprehensive Database: Coenzyme Q-10. Stockton (CA): Therapeutic Research Faculty; 1995-2007. [Accessed 2007-10-23]. Available from: http://www.naturaldatabase.com/(S(hhjwxb453fs5kk55sxqrp255))/nd/Search.aspx?cs=&s=ND&pt=100&id=938&ds=&name=CoQ10+(COENZYME+Q-10).
  • Kaikkonen J, Kosonen L, Nyyssonen K, Porkkala-Sarataho E, Salonen R, Korpela H, Salonen JT. Effect of combined coenzyme Q10 and d-alpha-tocopheryl acetate supplementation on exercise-induced lipid peroxidation and muscular damage: a placebo-controlled double-blind study in marathon runners. Free Radical Research 1998;29(1):85-92.
  • Kaikkonen J, Nyyssonen K, Porkkala-Sarataho E, Poulsen HE, Metsa-Ketela T, Hayn M, Salonen R, Salonen JT. Effect of oral coenzyme Q10 supplementation on the oxidation resistance of human VLDL+LDL fraction: absorption and antioxidative properties of oil and granule-based preparations. Free Radical Biology and Medicine 1997;22(7):1195-1202.
  • Kaikkonen J, Tuomainen TP, Nyyssonen K, Salonen JT. Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels. Free Radical Research 2002;36(4):389-397.
  • Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. American Journal of Cardiology 1985;56(4):247-251.
  • Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW, Gottlieb SS. The effect of coenzyme Q10 in patients with congestive heart failure. Annals of Internal Medicine 2000;132(8):636-640.
  • Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Molecular Aspects of Medicine 1994;15(Supplement 1):S143-S147.
  • Kurowska EM, Dresser G, Deutsch L, Bassoo E, Freeman DJ. Relative bioavailability and antioxidant potential of two coenzyme Q10 preparations. Annals of Nutrition and Metabolism 2003;47(1):16-21.
  • Langsjoen H, Langsjoen P, Langsjoen P, Willis R, Folkers K. Usefulness of coenzyme Q10 in clinical cardiology: a long-term study. Molecular Aspects of Medicine 1994;15(Supplement 1):S165-S175
  • Langsjoen P, Langsjoen P, Willis R, Folkers K. Treatment of essential hypertension with coenzyme Q10. Molecular Aspects of Medicine 1994;15(Supplement 1):S265-S272.
  • Langsjoen PH, Langsjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Molecular Aspects of Medicine 1997;18(Supplement 1):S145-S151.
  • Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10. Proceedings of the National Academy of Science 1985;82(12):4240-4244.
  • Langsjoen PH. The clinical use of HMG CoA-reductase inhibitors (statins) and the associated depletion of the essential cofactor coenzyme Q10; a review of pertinent human and animal data. Tyler (TX); 2002. [Accessed 2007-10-23]. Available from: http://www.fda.gov/ohrms/dockets/dailys/02/May02/052902/02p-0244-cp00001-02-Exhibit_A-vol1.pdf.
  • Levy HB, Kohlhaas HK. Considerations for supplementing with coenzyme Q10 during statin therapy. The Annals of Pharmacotherapy 2006;40(2):290-294.
  • Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10. Biochemical and Biophysical Research Communications 1994;199(3):1504-1508.
  • Lockwood K, Moesgaard S, Hanioka T, Folkers K. Apparent remission of breast cancer in high risk patients supplemented with nutritional antioxidants, essential fatty acids and coenzyme Q10. Molecular Aspects of Medicine 1994;15(Supplement 1):S231-S240.
  • Meletis CD, Jacobs T. Interactions between drugs and natural medicines. Sandy (OR): Eclectic Medical Publications; 1999.
  • Miles MV, Patterson BJ, Schapiro MB, Hickey FJ, Chalfonte-Evans M, Horn PS, Hotze SL. Coenzyme Q10 absorption and tolerance in children with Down syndrome: a dose-ranging trial. Pediatric Neurology 2006;35(1):30-37.
  • Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, Nicolai E, Romano M, Rosiello G, Cuocolo A. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Molecular Aspects of Medicine 1994;15(Supplement 1):S155-S163.
  • Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. The Clinical Investigator 1993;71(Supplement 8):S134-S136.
  • Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Molecular Aspects of Medicine 1997;18(Supplement 1):S137-S144.
  • Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"--a multinational trial. BioFactors 2003;18(1-4):79-89.
  • Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neuroscience Letters 2003;341(3):201-204.
  • Nakamura R, Littarru GP, Folkers K, Wilkinson EG. Study of CoQ10-enzymes in gingiva from patients with periodontal disease and evidence for a deficiency of Coenzyme Q10. Proceedings of the Nationall Academy of Science 1974;71(4):1456-1460.
  • NCI 2006: National Cancer Institute. Coenzyme Q10 (PDQ(R)) Health Professional Version. Bethesda (MD): National Cancer Institute, U.S. National Institutes of Health; 2006. [Accessed 2007-10-23]. Available from: http://www.cancer.gov/cancertopics/pdq/cam/coenzymeQ10/healthprofessional/allpages/print
  • NCI 2006: National Cancer Institute. Coenzyme Q10 (PDQ®) Patient Version. Bethesda (MD): National Cancer Institute, U.S. National Institutes of Health; 2006. [Accessed 2007-10-23]. Available from: http://www.cancer.gov/cancerinfo/pdq/cam/coenzymeQ10.
  • Overvad K, Diamant B, Holm L, Hølmer G, Mortensen SA, Stender S. Review: coenzyme Q10 in health and disease. European Journal of Clinical Nutrition 1999;53(10):764-770.
  • Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochimica et Biophysica Acta 1995;1271(1):275-280
  • Playford DA, Watts GF, Croft KD, Burke V. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 2003;168(1):169-179.
  • Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SGD, Sachdanandam P. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biological and Pharmaceutical Bulletin 2007;30(2):367-370.
  • Ravaglia G, Forti P, Maioli F, Bastagli L, Facchini A, Mariani E, Savarino L, Sassi S, Cucinotta D, Lenaz G. Effect of micronutrient status on natural killer cell immune function in healthy free-living subjects aged =90 y1-3. The American Journal of Clinical Nutrition 2000;71(2):590-598.
  • Reichenbach J, Schubert R, Schwan C, Muller K, Bohles HJ, Zielen S. Antioxidative capacity in patients with common variable immunodeficiency. Journal of Clinical Immunology 2000;20(3):221-226.
  • Roffe L, Schmidt K, Ernst E. Efficacy of Coenzyme Q10 for improved tolerability of cancer treatments: a systemic review. Journal of Clinical Oncology 2004;22(21):4418-4424.
  • Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. BioFactors 2003;18(1-4):91-100.
  • Sacher HL, Sacher ML, Landau SW, Kersten R, Dooley F, Sacher A, Sacher M, Dietrick K, Ichkhan K. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. American Journal of Therapeutics 1997;4(2-3):66-72.
  • Sander S, Coleman CI, Patel AA, Kluger J, White CM. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. Journal of Cardiac Failure 2006;12(6):464-472.
  • Sasaki K, Watanabe M, Suda Y, Ishizuka A, Nopartnaraporn N. Applications of photosynthetic bacteria for medical fields. Journal of Bioscience and Bioengineering 2005;100(5):481-488.
  • Savige GS. Candidate foods in the Asia-Pacific region for cardiovascular protection: fish, fruit and vegetables. Asia Pacific Journal of Clinical Nutrition 2001;10(2):134-137.
  • Shults CW, Beal MF, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Experimental Neurology 2004;188(2):491-494.
  • Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Archives of Neurology 2002;59(10):1541-1550.
  • Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacology and Therapeutics 2005;107(1):120-130.
  • Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molecular Aspects of Medicine 1997;18(Supplement 1):S159-S168.
  • Strazisar M, Fir M, Golc-Wondra A, Milivojevic L, Prosek M, Abram V. Quantitative determination of coenyzme Q10 by liquid chromatography and liquid chromatography/mass spectrometry in dairy products. Journal of AOAC International 2005;88(4):1020-1027.
  • Strijks E, Kremer HP, Horstink MW. Q10 therapy in patients with idiopathic Parkinson's disease. Molecular Aspects of Medicine 1997;18(Supplement 1):S237-S240.
  • Swiezewska E, Dallner G, Andersson B, Ernster L. Biosynthesis of ubiquinone and plastoquinone in the endoplasmic reticulum-Golgi membranes of spinach leaves. The Journal of Biological Chemistry 1993;268(2):1494-1499.
  • The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57(3):397-404.
  • The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68(1):20-28.
  • Tournas JA, Lin FH, Burch JA, Selim MA, Monteiro-Riviere NA, Zielinski JE, Pinnell SR. Ubiquinone, Idebenone, and kinetin provide ineffective photoprotection to skin when compared to a topical antioxidant combination of vitamins C and E with Ferulic acid. Journal of Investigative Dermatology 2006;126(5):1185-1187.
  • Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21(7):797-806.
  • Tsuneki H, Sekizaki N, Suzuki T, Kobayashi S, Wada T, Okamoto T, Kimura I, Sasaoka T. Coenzyme Q(10) prevents high glucose-induced oxidative stress in human umbilical vein endothelial cells. European Journal of Pharmacology 2007;566(1-3):1-10.
  • Turunen M, Wehlin L, Sjoberg M, Lundahl J, Dallner G, Brismar K, Sindelar PJ. beta2-Integrin and lipid modifications indicate a non-antioxidant mechanism for the anti-atherogenic effect of dietary coenzyme Q10. Biochemical and Biophysical Research Communications 2002;296(2):255-260.
  • Watson JP, Jones DE, James OF, Cann PA, Bramble MG. Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study. Journal of Gastroenterology and Hepatology 1999;14(10):1034-1040.
  • Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. Journal of the American College of Cardiology 1999;33(6):1549-1552.
  • Watts GF, Playford DA, Croft KD, Ward NC, Mori TA, Burke V. Coenzyme Q10 improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia 2002;45(3):420-426.
  • Watts TL. Coenzyme Q10 and periodontal treatment: is there any beneficial effect? British Dental Journal 1995;178(6):209-213.
  • Weant KA, Smith KM. The role of coenzyme Q10 in heart failure. Annals of Pharmacotherapy 2005;39(9):1522-1526.
  • Weber C, Jakobsen TS, Mortensen SA, Paulsen G, Hølmer G. Antioxidative effect of dietary coenzyme Q10 in human blood plasma. International Journal for Vitamin and Nutrition Research 1994;64(4):311-315.
  • Weber C, Jakobsen TS, Mortensen SA, Paulsen G, Hølmer G. Effect of dietary coenzyme Q10 as an antioxidant in human plasma. Molecular Aspects of Medicine 1994;15(Supplement 1):S97-S102.
  • Weston SB, Zhou S, Weatherby RP, Robson SJ. Does exogenous coenzyme Q10 affect aerobic capacity in endurance athletes? International Journal of Sport and Nutrition 1997;7(3):197-206.
  • Wilkinson EG, Arnold RM, Folkers K. Bioenergetics in clinical medicine. VI. adjunctive treatment of periodontal disease with coenzyme Q10. Research Communications in Chemical Pathology and Pharmacology 1976;14(4):715-719.
  • Yamagami T, Shibata N, Folkers K. Study of coenzyme Q10 in essential hypertension. In: Folkers K, Yamamura, editors. Biomedical and Clinical Aspects of Coenzyme Q. Amsterdam (NL): Elsevier/North-Holland Biomedical Press; 1977.
  • Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Ameliorating effect of coenzyme Q(10), riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clinical Biochemistry 2007;40(9-10):623-628.
  • Zülli F, Belser E, Schmid D, Liechti C, Suter F. Preparation and properties of coenzyme Q10 nanoemulsions. Hertfordshire (UK): Cosmetic Science Technology; 2006. [Accessed 2007-10-24]. Available from: http://www.mibellebiochemistry.com/pdfs/Preparation_and_Properties_of_Coenzyme_Q10_Nanoemulsions_Cosm_Sci_Technol_2006.pdf.